(NASDAQ: BCDA) Biocardia's forecast annual revenue growth rate of 221.83% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Biocardia's revenue in 2025 is $3,000.On average, 1 Wall Street analysts forecast BCDA's revenue for 2025 to be $517,789, with the lowest BCDA revenue forecast at $517,789, and the highest BCDA revenue forecast at $517,789. On average, 1 Wall Street analysts forecast BCDA's revenue for 2026 to be $517,789, with the lowest BCDA revenue forecast at $517,789, and the highest BCDA revenue forecast at $517,789.
In 2027, BCDA is forecast to generate $517,789 in revenue, with the lowest revenue forecast at $517,789 and the highest revenue forecast at $517,789.